证券代码：002693 证券简称：*ST双成 公告编号：2025-050 海南双成药业股份有限公司 2025年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示： 1、本次股东会没有出现否决议案的情形。 2、本次股东会没有涉及变更前次股东会决议。 一、会议召开和出席情况 1、现场会议召开时间：2025年7月31日（星期四）下午14：30 网络投票时间：2025年7月31日 （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年7 月31日9:15-9:25，9:30-11:30和13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的时间为2025年7月31日 9:15-15:00期间的任意时间。 6、本次股东会会议的召集、召开和表决程序符合《中华人民共和国公司法》 《中华人民共和国证券法》《深圳证券交易所股票上市规则》《深圳证券交易所上 市公司自律监管指引第1号——主板上市公司规范运作》和《海南双成药业股份 有限公司章程》等规定。 7、出席会议的股东（含网络投票）共596人，代表股份213,952, ...

Core Viewpoint - Hainan Shuangcheng Pharmaceutical Co., Ltd. (referred to as "Shuangcheng Pharmaceutical") reported a significant decline in revenue and an expanded net loss for the first half of 2025, raising concerns about its potential delisting if it fails to turn around its financial performance by the end of the year [1][5]. Financial Performance - For the first half of 2025, Shuangcheng Pharmaceutical achieved operating revenue of 84.12 million yuan, a year-on-year decrease of 11.35% [1]. - The net loss attributable to shareholders was 18.47 million yuan, worsening from previous losses [1]. - Revenue has been consistently declining over the past three years, with figures of 275 million yuan, 236 million yuan, and 174 million yuan for 2022, 2023, and 2024 respectively, reflecting year-on-year declines of 14.22%, 14.18%, and 26.16% [3]. Industry Challenges - The pharmaceutical industry is facing increased scrutiny and regulatory measures, impacting Shuangcheng Pharmaceutical's operations in the peptide market [2]. - Rising costs of raw materials due to stricter environmental regulations have further pressured the company's production costs [2]. Strategic Moves - Shuangcheng Pharmaceutical attempted a strategic shift by planning a major asset restructuring to acquire shares in Ningbo Aura Semiconductor Co., Ltd. (referred to as "Aura"), aiming to transition into the semiconductor industry [6][7]. - The stock price surged significantly following the announcement of this acquisition, reaching a peak of 40.98 yuan per share, a cumulative increase of 685% [7]. Failed Transformation - The acquisition of Aura was ultimately terminated due to disagreements on transaction terms and expectations among the parties involved [8]. - The failure of this transformation effort has compounded the company's operational challenges and financial instability [11]. Current Strategies - Shuangcheng Pharmaceutical is focusing on cost control and enhancing its sales strategies to mitigate the risk of delisting [9][10]. - The company is working to expand its export business and improve its product quality while maintaining existing customer orders [9]. - Despite these efforts, doubts remain about the effectiveness of these strategies given the ongoing pressures in the pharmaceutical industry and limited resources for research and market expansion [11].

金融界消息 截至2025年7月31日收盘，*ST双成（002693）报收于8.3元，上涨4.4%，换手率7.15%，成 交量29.40万手，成交金额2.44亿元。 资金流向方面，今日主力资金净流入3752.16万元，占比成交额15.39%。其中，超大单净流入1533.26万 元、占成交额6.29%，大单净流入2218.90万元、占成交额9.1%，中单净流出流出1622.48万元、占成交 额6.66%，小单净流出2129.69万元、占成交额8.74%。 天眼查商业履历信息显示，海南双成药业股份有限公司，成立于2000年，位于海口市，是一家以从事医 药制造业为主的企业。企业注册资本41468.975万人民币，实缴资本41468.975万人民币。公司法定代表 人为王成栋。 通过天眼查大数据分析，海南双成药业股份有限公司共对外投资了2家企业，参与招投标项目141次，知 识产权方面有商标信息28条，专利信息15条，此外企业还拥有行政许可301个。 来源：金融界 *ST双成最新一期业绩显示，截至2025中报，公司营业总收入8412.21万元、同比减少11.35%，归属净利 润1846.66万元，同比减少8.97%，扣非净 ...

Summary of Key Points Core Viewpoint - In July 2023, 19 companies released their semi-annual reports for 2025, with 12 companies reporting year-on-year profit growth and 7 reporting declines. Notably, 10 companies experienced simultaneous growth in both net profit and revenue, while 6 companies saw declines in both metrics. The most significant profit increase was reported by Dong'an Power, with a growth rate of 157.75% [1]. Group 1: Company Performance - Dong'an Power reported earnings per share of 0.0167, with a net profit of 3.92 million and a year-on-year increase of 157.75%. Revenue reached 247.91 million, up 25.72% [1]. - Ding Tong Technology achieved an earnings per share of 0.8300, net profit of 115.40 million, and a year-on-year increase of 134.06%. Revenue was 78.46 million, up 73.51% [1]. - Zhiwei Intelligence reported earnings per share of 0.4100, net profit of 10.17 million, with an 80.08% year-on-year increase. Revenue was 194.69 million, up 15.29% [1]. - Huijia Times reported earnings per share of 0.1425, net profit of 6.70 million, with a year-on-year increase of 62.64%. Revenue was 127.12 million, up 2.29% [1]. - Ningde Times reported earnings per share of 6.9200, net profit of 3,048.51 million, with a year-on-year increase of 33.33%. Revenue was 17,888.63 million, up 7.27% [1]. Group 2: Declining Performance - Anada reported a loss per share of -0.1222, with a net loss of 2.63 million, reflecting a year-on-year decline of 158.08%. Revenue was 87.59 million, down 10.51% [2]. - Weitong Communication reported earnings per share of 0.0675, with a net profit of 3.10 million, down 68.57% year-on-year. Revenue was 35.99 million, down 24.62% [2]. - New Tian Pharmaceutical reported earnings per share of 0.0236, with a net profit of 576.61 thousand, down 80.99% year-on-year. Revenue was 35.83 million, down 18.88% [2].

Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, indicating challenges in the pharmaceutical industry and the need for strategic adjustments to improve performance [2][4]. Financial Performance - Revenue for the first half of 2025 was CNY 84,122,087.60, a decrease of 11.35% compared to CNY 94,892,601.28 in the same period last year [2][4]. - The net profit attributable to shareholders was a loss of CNY 18,466,557.74, compared to a loss of CNY 16,946,164.02 in the previous year, reflecting an 8.97% increase in losses [2][4]. - The net cash flow from operating activities improved significantly, with a net outflow of CNY 1,590,356.53, a 93.23% improvement from a net outflow of CNY 23,505,112.58 in the previous year [2][4]. Industry Overview - The pharmaceutical manufacturing industry in China saw a revenue of CNY 1,227.52 billion in the first half of 2025, down 1.2% year-on-year, with total profits decreasing by 2.8% to CNY 176.69 billion [3]. - The company is recognized as a national high-tech enterprise, focusing on the research, production, and sales of peptide drugs, with several products approved for sale in international markets [3][4]. Business Operations - The company specializes in the development, production, and sales of injectable drugs, solid preparations, and active pharmaceutical ingredients, with a strong emphasis on chemical synthesis of peptide drugs [3][4]. - Key products include Thymosin Alpha 1, Somatostatin, and Bivalirudin, which have received various international approvals, including from the FDA and EMA [3][4]. Competitive Advantages - The company has established a comprehensive capability in generic drug research, registration, and patent management, with a robust pipeline of products aimed at international markets [4]. - The company has initiated the development of new peptide synthesis technologies to reduce environmental impact and production costs, enhancing its competitive edge [4].

| 海南双成药业股份有限公司 | | | 2025 年半年度报告摘要 | | | --- | --- | --- | --- | --- | | 证券代码：002693 | 证券简称：*ST 双成 | | 公告编号：2025-049 | | | 海南双成药业股份有限公司 | | | | | | 一、重要提示 | | | | | | 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划， | | | | | | 投资者应当到证监会指定媒体仔细阅读半年度报告全文。 | | | | | | 所有董事均已出席了审议本报告的董事会会议。 | | | | | | 非标准审计意见提示 | | | | | | □适用 ?不适用 | | | | | | 董事会审议的报告期利润分配预案或公积金转增股本预案 | | | | | | □适用 ?不适用 | | | | | | 公司计划不派发现金红利，不送红股，不以公积金转增股本。 | | | | | | 董事会决议通过的本报告期优先股利润分配预案 | | | | | | □适用 ?不适用 | | | | | | 二、公司基本情况 | | | | | ...

证券代码：002693 证券简称：*ST双成 公告编号：2025-048 海南双成药业股份有限公司 第五届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 于巨潮资讯网（http://www.cninfo.com.cn/），摘要同时刊登于《证券时报》 《中国 证券报》。 一、董事会会议召开情况 海南双成药业股份有限公司（以下简称"公司"）第五届董事会第二十次会 议通知于 2025 年 7 月 18 日以书面送达或电子邮件等方式发出，并于 2025 年 7 月 30 日 9:00 以现场结合通讯表决的方式召开。会议应出席董事 6 人，实际参加 表决的董事 6 人。本次会议由董事长王成栋先生主持，会议的召开符合有关法律 法规、公司章程的规定。 二、董事会会议审议情况 （一）审议通过《关于审议 2025 年半年度报告全文及摘要的议案》 表决情况：同意 6 票，反对 0 票，弃权 0 票。 本议案已经公司董事会审计委员会审议通过，并同意提交董事会审议。 《海南双成药业股份有限公司 2025 年半年度报告》全文及摘要于同日刊登 （二）审议通过《 ...

海南双成药业股份有限公司 董事、高级管理人员离职管理制度 海南双成药业股份有限公司 董事、高级管理人员离职管理制度 （2025 年 7 月制定） 第一章 总 则 第一条 为规范海南双成药业股份有限公司（以下简称"公司"）董事、高 级管理人员离职相关事宜，确保公司治理结构的稳定性和连续性，维护公司及股 东的合法权益，公司根据《中华人民共和国公司法》 《上市公司章程指引》 《深圳 证券交易所股票上市规则》等法律、法规、规范性文件及《海南双成药业股份有 限公司章程》 （以下简称"《公司章程》"）的有关规定，结合公司实际情况，制定 本制度。 第二条 本制度适用于公司全体董事（含独立董事）及高级管理人员因任 期届满、辞任、被解除职务或其他原因离职的情形。 第二章 离职情形与生效条件 第三条 董事、高级管理人员候选人的任职资格应当符合法律法规、深圳 证券交易所业务规则和《公司章程》等规定。存在下列情形之一的，不得担任公 司董事或者高级管理人员： （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩 序，被判处刑罚，或者因犯罪被剥夺政治权利，执行期满未逾 5 年，被宣 ...

*ST双成2025半年报 ...

*ST双成（SZ 002693，收盘价：7.95元）7月30日晚间发布半年度业绩报告称，2025年上半年营业收入 约8412万元，同比减少11.35%；归属于上市公司股东的净利润亏损约1847万元；基本每股收益亏损 0.0445元。2024年同期营业收入约9489万元；归属于上市公司股东的净利润亏损约1695万元；基本每股 收益亏损0.0409元。 （文章来源：每日经济新闻） ...